294 related articles for article (PubMed ID: 30117265)
21. Measurement of Developmental and Behavioral Concerns in Toddlers With Tuberous Sclerosis Complex.
McDonald NM; Jacobs S; Hyde C; Kasari C; Jeste SS
Pediatr Neurol; 2024 Jun; 155():62-67. PubMed ID: 38603983
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for the development of autism spectrum disorder in children with tuberous sclerosis complex: protocol for a systematic review.
Mitchell R; Barton S; Harvey AS; Williams K
Syst Rev; 2017 Mar; 6(1):49. PubMed ID: 28270230
[TBL] [Abstract][Full Text] [Related]
23. A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance.
Alsowat D; Zak M; McCoy B; Kabir N; Al-Mehmadi S; Chan V; Whitney R
Pediatr Neurol; 2020 Jan; 102():44-48. PubMed ID: 31362847
[TBL] [Abstract][Full Text] [Related]
24. Tuberous sclerosis complex-associated neuropsychiatric disorder (TAND) in a low-resource setting - From seizure to psychosis: A case report.
Pokharel S; Jyotsana P; Maharjan RS; Singh R; Pandit K
Ann Med Surg (Lond); 2020 Dec; 60():734-736. PubMed ID: 33425343
[TBL] [Abstract][Full Text] [Related]
25. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
van Andel DM; Sprengers JJ; Oranje B; Scheepers FE; Jansen FE; Bruining H
Mol Autism; 2020 May; 11(1):30. PubMed ID: 32381101
[TBL] [Abstract][Full Text] [Related]
26. Tuberous sclerosis complex-associated neuropsychiatric disorders.
Marcinkowska AB; Tarasewicz A; Jóźwiak S; Dębska-Ślizień A; Szurowska E
Psychiatr Pol; 2022 May; ():1-20. PubMed ID: 36370437
[TBL] [Abstract][Full Text] [Related]
27. Self-injury and aggression in adults with tuberous sclerosis complex: Frequency, associated person characteristics, and implications for assessment.
Wilde L; Eden K; de Vries P; Moss J; Welham A; Oliver C
Res Dev Disabil; 2017 May; 64():119-130. PubMed ID: 28411579
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Psychiatric Symptoms on Tuberous Sclerosis Complex and Utilization of Mental Health Treatment.
Mowrey KE; Ashfaq M; Pearson DA; Hashmi SS; Roberds SL; Farach LS; Northrup H
Pediatr Neurol; 2019 Feb; 91():41-49. PubMed ID: 30527288
[TBL] [Abstract][Full Text] [Related]
29. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial.
Randell E; McNamara R; Davies DM; Owen-Jones E; Kirby N; Angel L; Drew C; Cannings-John R; Smalley M; Saxena A; McDermott E; Stockwell L; de Vries PJ; Hood K; Sampson JR
Trials; 2016 Aug; 17():398. PubMed ID: 27515417
[TBL] [Abstract][Full Text] [Related]
30. The role of glia in epilepsy, intellectual disability, and other neurodevelopmental disorders in tuberous sclerosis complex.
Wong M
J Neurodev Disord; 2019 Dec; 11(1):30. PubMed ID: 31838997
[TBL] [Abstract][Full Text] [Related]
31. Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
Curatolo P; Moavero R; de Vries PJ
Lancet Neurol; 2015 Jul; 14(7):733-45. PubMed ID: 26067126
[TBL] [Abstract][Full Text] [Related]
32. Development and Feasibility of the Self-Report Quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ).
Heunis TM; Chambers N; Vanclooster S; Bissell S; Byars AW; Capal JK; Cukier S; Davis PE; de Vries MC; De Waele L; Flinn J; Gardner-Lubbe S; Gipson T; Kingswood JC; Krueger DA; Kumm AJ; Sahin M; Schoeters E; Smith C; Srivastava S; Takei M; van Eeghen AM; Waltereit R; Jansen AC; de Vries PJ
Pediatr Neurol; 2023 Oct; 147():101-123. PubMed ID: 37598571
[TBL] [Abstract][Full Text] [Related]
33. Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex.
Kilincaslan A; Kok BE; Tekturk P; Yalcinkaya C; Ozkara C; Yapici Z
J Child Adolesc Psychopharmacol; 2017 May; 27(4):383-388. PubMed ID: 27797585
[TBL] [Abstract][Full Text] [Related]
34. Advances in the treatment of tuberous sclerosis complex.
Leclezio L; de Vries PJ
Curr Opin Psychiatry; 2015 Mar; 28(2):113-20. PubMed ID: 25602245
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychological attention deficits in tuberous sclerosis complex (TSC).
de Vries PJ; Gardiner J; Bolton PF
Am J Med Genet A; 2009 Mar; 149A(3):387-95. PubMed ID: 19215038
[TBL] [Abstract][Full Text] [Related]
36. Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND).
de Vries PJ; Leclezio L; Gardner-Lubbe S; Krueger D; Sahin M; Sparagana S; De Waele L; Jansen A
Orphanet J Rare Dis; 2021 Oct; 16(1):447. PubMed ID: 34689816
[TBL] [Abstract][Full Text] [Related]
37. Best use of the tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) checklist.
de Vries PJ; Jansen A
Dev Med Child Neurol; 2019 Feb; 61(2):112-113. PubMed ID: 30378680
[No Abstract] [Full Text] [Related]
38. White matter disruption is associated with persistent seizures in tuberous sclerosis complex.
Moavero R; Napolitano A; Cusmai R; Vigevano F; Figà-Talamanca L; Calbi G; Curatolo P; Bernardi B
Epilepsy Behav; 2016 Jul; 60():63-67. PubMed ID: 27179194
[TBL] [Abstract][Full Text] [Related]
39. Behavioral and cognitive aspects of tuberous sclerosis complex.
Prather P; de Vries PJ
J Child Neurol; 2004 Sep; 19(9):666-74. PubMed ID: 15563012
[TBL] [Abstract][Full Text] [Related]
40. Sleep disorders and neuropsychiatric disorders in a pediatric sample of tuberous sclerosis complex: a questionnaire-based study.
Moavero R; Voci A; La Briola F; Matricardi S; Toldo I; Mancardi MM; Negrin S; Messana T; Mazzone L; Valeriani M; Curatolo P; Bruni O
Sleep Med; 2022 Jan; 89():65-70. PubMed ID: 34915263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
